)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sonnet BioTherapeutics Holdings (SONN) investor relations material
Sonnet BioTherapeutics Holdings Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Aug, 2025
Executive summary
Focused on oncology and immunotherapy, advancing clinical programs for SON-1010, SON-080, and SON-1210, with recent clinical trial expansions and new licensing agreements in India and collaborations with Roche and Sarcoma Oncology Center.
Entered a business combination agreement in July 2025 to become a wholly owned subsidiary of Hyperliquid Strategies, Inc., with legacy shareholders receiving contingent value rights.
Raised $18.0 million in July 2025 through convertible notes, preferred stock, warrants, and warrant exercises to address liquidity needs.
Financial highlights
Net loss of $3.8 million for the quarter and $10.4 million for the nine months ended June 30, 2025, compared to $3.5 million and $4.3 million, respectively, in the prior year periods.
Collaboration revenue of $1.0 million for the nine months ended June 30, 2025, from the Alkem Agreement; $18,626 in the prior year from the New Life Agreement.
Research and development expenses increased to $2.4 million for the quarter and $6.2 million for the nine months, driven by clinical trial costs and license fees.
General and administrative expenses were $1.4 million for the quarter and $5.7 million for the nine months, up year-over-year due to higher professional fees.
Cash balance of $0.3 million as of June 30, 2025; net cash used in operations was $7.1 million for the nine months.
Outlook and guidance
Cash on hand plus July 2025 financings expected to fund operations into February 2026; substantial additional financing will be needed beyond that period.
Ongoing and upcoming milestones include topline efficacy data for SON-1010 in H2 2025, Alkem's initiation of a Phase 2 trial for SON-080, and first patient dosing for SON-1210 in H2 2025.
Expenses and operating losses expected to increase as clinical programs advance and commercialization activities expand.
Explain the Alkem agreement's impact on SON-080.
Assess the risks of HYPE treasury strategy.
Detail SON-1010's clinical trial expansion.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sonnet BioTherapeutics Holdings earnings date
Q4 202512 Dec, 2025
Next Sonnet BioTherapeutics Holdings earnings date
Q4 202512 Dec, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sonnet BioTherapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development of innovative biologic drugs for cancer and other serious diseases. The company utilizes a proprietary platform to design fully human fusion proteins that enhance the therapeutic activity and delivery of cytokines. Sonnet’s pipeline targets various solid tumors and immunological conditions, with development efforts supported by preclinical and clinical research. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage